Bmab1800

BIOLOGICAL2 trials

Sponsors

Biocon Biologics UK PLC

Conditions

Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)Cancer

Phase 1

Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma

RecruitingNCT07581509

Biocon Biologics UK PLCAdult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)

Start: 2026-06-29End: 2028-06-21Target: 138Updated: 2026-10-02

Pharmacokinetics, safety, and immunogenicity of Bmab1800 and Keytruda® as adjuvant monotherapy in patients with melanoma.

Active, not recruitingPACTR202605570676346

Biocon Biologics UK PLCCancer

Start: 2026-08-01Target: 36Updated: 2026-09-14